Lutetium-177-PSMA-617: A Vision of the Future

Elias Chandran; William D. Figg; Ravi Madan

doi:10.1080/15384047.2022.2037985

Lutetium-177-PSMA-617: A Vision of the Future

Elias Chandran, William D. Figg^*, Ravi Madan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[¹⁷⁷Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [¹⁷⁷Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [¹⁷⁷Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION’s design could not allow it. In both trials, [¹⁷⁷Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [¹⁷⁷Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.

Original language	English
Pages (from-to)	186-190
Number of pages	5
Journal	Cancer Biology and Therapy
Volume	23
Issue number	1
DOIs	https://doi.org/10.1080/15384047.2022.2037985
State	Published - 2022
Externally published	Yes

Keywords

FDG PET-CT
PSMA
Prostate cancer
cabazitaxel
lutetium
mCRPC
radioligand therapy

Access to Document

10.1080/15384047.2022.2037985

Cite this

@article{8b4aea75355941bbbcbfa3d4fedeb71d,

title = "Lutetium-177-PSMA-617: A Vision of the Future",

abstract = "In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [177Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [177Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION{\textquoteright}s design could not allow it. In both trials, [177Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [177Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.",

keywords = "FDG PET-CT, PSMA, Prostate cancer, cabazitaxel, lutetium, mCRPC, radioligand therapy",

author = "Elias Chandran and Figg, {William D.} and Ravi Madan",

note = "Publisher Copyright: {\textcopyright} This work was authored as part of the Contributor{\textquoteright}s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.",

year = "2022",

doi = "10.1080/15384047.2022.2037985",

language = "English",

volume = "23",

pages = "186--190",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

number = "1",

}

TY - JOUR

T1 - Lutetium-177-PSMA-617

T2 - A Vision of the Future

AU - Chandran, Elias

AU - Figg, William D.

AU - Madan, Ravi

N1 - Publisher Copyright: © This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

PY - 2022

Y1 - 2022

N2 - In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [177Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [177Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION’s design could not allow it. In both trials, [177Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [177Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.

AB - In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [177Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [177Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION’s design could not allow it. In both trials, [177Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [177Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.

KW - FDG PET-CT

KW - PSMA

KW - Prostate cancer

KW - cabazitaxel

KW - lutetium

KW - mCRPC

KW - radioligand therapy

UR - http://www.scopus.com/inward/record.url?scp=85125427908&partnerID=8YFLogxK

U2 - 10.1080/15384047.2022.2037985

DO - 10.1080/15384047.2022.2037985

M3 - Article

C2 - 35220877

AN - SCOPUS:85125427908

SN - 1538-4047

VL - 23

SP - 186

EP - 190

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 1

ER -

Lutetium-177-PSMA-617: A Vision of the Future

Abstract

Keywords

Access to Document

Fingerprint

Cite this